Despite many treatment strategies available for metastatic renal cell carcinoma (mRCC), predictive biomarkers of response to immunotherapy are still needed. In this context, growing efforts have been devoted to translational research, especially focusing on the immune tumor microenvironment (I-TME).
The Me...
S. E. Rebuzzi, F. Catalano, Francesca Schiavi et al.· Cancer Immunology and Immuno...· 0 citations
Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...
A. A. Valsecchi, M. Maffezzoli, M. Cursano et al.· Cancer Metastasis Review· 0 citations
An ethnicity-based benchmarking analysis of therapeutic outcomes across standard-of-care ICI combination regimens demonstrates consistent clinical efficacy across Asian and Caucasian populations, with no statistically significant or clinically meaningful divergence in ORR or PFS.
D. Khanna, T. Dey, E. Blanchard-Cavagis et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.